{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.0","upperLimit":"25.8","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants in the analysis population who experienced a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) and was assessed using RECIST 1.1 based on BICR evaluation. The percentage of participants who experienced a CR or PR in Cohort B2 was presented for the first course of pembrolizumab treatment per protocol.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab, 200 mg, IV once every 3 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"OG000","title":"Cohort B2: Head & Neck Cancer Expansion"}],"paramType":"NUMBER","populationDescription":"The population consisted of all Cohort B2 participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression (Up to ~ 35 months) - through FA cutoff date 26 Apr 2016","title":"Overall RECIST 1.1 Response Rate Based on BICR Review for Participants in Cohort B2","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}